Key Trend Reshaping the Neonatal Respiratory Distress Syndrome Treatment Market in 2025: Advancements In Non-Invasive Respiratory Treatments For Neonates With Hypoxic Respiratory Failure

What industry-specific factors are fueling the growth of the neonatal respiratory distress syndrome treatment market?
The neonatal respiratory distress syndrome treatment market's growth is anticipated to be driven by the increasing rate of premature births. Premature birth, also known as preterm birth, is when a child is born before the 37th week of pregnancy. Infants born prior to the 32nd week are at the highest risk of severe health complications given that a typical pregnancy lasts about 40 weeks. An uptick in premature births is attributable to factors such as advanced maternal age, multiple pregnancies, health conditions, lifestyle choices, fertility treatment usage, infections, and environmental factors. Neonatal respiratory distress syndrome (NRDS) treatment is often necessary for premature infants due to their underdeveloped lungs and insufficient surfactant production. This treatment aids in lung function improvement, breathing stabilization, and the reduction of respiratory failure risk in premature infants. For example, in December 2022, a report by Tommy's, a charity based in the UK, indicated that premature live births in England and Wales rose to 7.9% in 2022, from 7.5% the previous year. This signifies the second straight year of premature birth increases, with over 53,000 babies born prematurely in 2022 alone. As a result, the escalating prevalence of premature births is fueling the expansion of the neonatal respiratory distress syndrome treatment market.

Get Your Neonatal Respiratory Distress Syndrome Treatment Market Report Here:
https://www.thebusinessresearchcompany.com/report/neonatal-respiratory-distress-syndrome-treatment-global-market-report

What Is the projected market size and growth rate for the neonatal respiratory distress syndrome treatment market?
The market for treatment of neonatal respiratory distress syndrome has seen robust growth in the past few years. The market is projected to expand from $0.96 billion in 2024 to $1.03 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.3%. Factors contributing to the historical growth include increased alveoli permeability and fluid buildup, heightened alveolar-capillary permeability, a rise in the use of mechanical ventilation, heightened awareness among healthcare providers and parents concerning the significance of neonatal care, and increased expenditure in healthcare.

Over the coming years, the neonatal respiratory distress syndrome treatment market is projected to witness robust growth. It is predicted to reach to $1.41 billion by 2029, expanding at an 8.0% compound annual growth rate (CAGR). The growth during this projection period is anticipated to be driven by factors such as a heightened preference for accessories and consumables, a surge in NICU admissions, escalating demand for tailored medicine, a rise in premature births, and an upswing in research and development activities. Notable trends slated for this forecast period encapsulate the automation of neonatal intensive care units (NICUs), artificial intelligence (AI) integration, technological advancements in neonatal care, innovations in surfactant therapy, and the evolution of ventilator technologies.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20899&type=smp

What new trends are reshaping the neonatal respiratory distress syndrome treatment market and its opportunities?
In order to enhance oxygenation, reduce respiratory complications, and provide non-invasive treatments for newborns with hypoxic respiratory failure, notable companies in the neonatal respiratory distress syndrome treatment market are focusing on developing superior technologies, such as nitric oxide generators. A nitric oxide generator is a medical equipment that creates and dispenses nitric oxide gas, typically used to address respiratory problems by raising oxygenation and alleviating pulmonary hypertension, particularly in newborns and seriously ill patients. As an example, in June 2022, Beyond Air Inc., a medical device and biopharmaceutical firm based in the US, was granted FDA approval for LungFit PH. This revolutionary nitric oxide generator is crafted to treat full-term and near full-term newborns suffering from hypoxic respiratory failure, including persistent pulmonary hypertension of the newborn (PPHN). Utilizing Beyond Air's patented Ionizer technology, the device manufactures nitric oxide as needed from the surrounding air, offering an unending supply without concerns over dosage or flow. The equipment uses a low-power compressor to ionize nitrogen and oxygen, thereby minimizing the production of nitrogen dioxide (NO2), which is then safely eliminated through a smart filter.

What major market segments define the scope and growth of the neonatal respiratory distress syndrome treatment market?
The neonatal respiratory distress syndrome treatment market covered in this report is segmented -

1) By Therapy: Oxygen Therapy, Surfactant Therapy
2) By Route Of Administration: Parenteral, Inhalation, Other Routes Of Administration
3) By End User: Hospitals, Sub-Acute Facilities, Home Care, Retail Pharmacies

Subsegments:
1) By Oxygen Therapy: Conventional Oxygen Therapy, High-Flow Nasal Cannula (HFNC) Oxygen Therapy, Continuous Positive Airway Pressure (CPAP) Oxygen Therapy, Invasive Mechanical Ventilation With Oxygen Therapy
2) By Surfactant Therapy: Natural Surfactants, Synthetic Surfactants, Combined Surfactant Therapy (Natural + Synthetic), Prophylactic Surfactant Therapy, Rescue Surfactant Therapy

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20899

Which region dominates the neonatal respiratory distress syndrome treatment market?
North America was the largest region in the neonatal respiratory distress syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neonatal respiratory distress syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which key market leaders are driving the neonatal respiratory distress syndrome treatment industry growth?
Major companies operating in the neonatal respiratory distress syndrome treatment market are Merck & Co. Inc., AbbVie Inc., Bayer AG, Abbott Laboratories, Medtronic Plc, Medline Industries, Becton Dickinson, Stryker Corporation, GE Healthcare, Koninklijke Philips NV, ResMed Inc., Drägerwerk AG & Co. KGaA, Chiesi Farmaceutici, ICU Medical Inc., Fisher & Paykel Healthcare, Vyaire Medical, Laerdal Medical, Hamilton Medical, Inspiration Healthcare, Ventec Life Systems, Neotech Products, Aerogen Pharma Corp., Windtree Therapeutics Inc., Discovery Laboratories Inc., Lyomark Pharma GmbH

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=20899&type=smp

What Is Covered In The Neonatal Respiratory Distress Syndrome Treatment Global Market Report?

•Market Size Forecast: Examine the neonatal respiratory distress syndrome treatment market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the neonatal respiratory distress syndrome treatment market for a structured understanding.
•Key Players Overview: Analyze major players in the neonatal respiratory distress syndrome treatment market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the neonatal respiratory distress syndrome treatment market.
•Segment Contributions: Evaluate how different segments drive overall growth in the neonatal respiratory distress syndrome treatment market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the neonatal respiratory distress syndrome treatment market.
•Industry Challenges: Identify potential risks and obstacles affecting the neonatal respiratory distress syndrome treatment market.
•Competitive Landscape: Review strategic developments in the neonatal respiratory distress syndrome treatment market, including expansions, agreements, and new product launches.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.